A clnical study to assess inhibitory effect of bepotastine besilate OD tablet to compare with fexofenadine hydrochloride and pseudoephedrine hydrochloride combination tablet in patients with cedar pollinosis in the OHIO Chamber.

A clnical study to assess inhibitory effect of bepotastine besilate OD tablet to compare with fexofenadine hydrochloride and pseudoephedrine hydrochloride combination tablet in patients with cedar pollinosis in the OHIO Chamber. - A clnical study to assess inhibitory effect of bepotastine besilate OD tablet to compare with fexofenadine hydrochloride and pseudoephedrine hydrochloride combination tablet in patients with cedar pollinosis in the OHIO Chamber.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010687

Enrollment

Registered

2013-05-25

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar Pollinosis

Interventions

Term I: placebo Term II: test drug or reference drug Term III: reference drug or test drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CAPRAST score against Japanese cedar pollen from 2 to 6 within the last 2 years. Patient whom the nose symptom that was apparent to the cedar pollen scattering period past 2 years developed in.

Exclusion criteria

Exclusion criteria: 1)Patients with mucosal lesion of the nose and eyes. 2)Patients with severe or requiring treatment needed Allergic Rhinitis. 3)Patients who received steroid injections within 6 months. 4)Patients with respiratory disease such as asthma. 5)Patients with past history of anaphylaxis. 6)Patients who have anaphylaxis with these drugs. 7)Patients with pregnancy, delivery or lactation.

Design outcomes

Primary

Measure	Time frame
Subjective symptoms	—

Secondary

Measure	Time frame
Nasal secretion volume Number of sneezing Exercise-based treatment programs	—

Countries

Japan

Contacts

Public ContactSatoko Shimizu

Tokyo Reserch Center of Clinical Pharmacology co.,ltd. Customer Relations Dept.

s-shimizu@trcp.co.jp03-5366-3454

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026